首页> 外文OA文献 >A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer

【2h】

A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer

机译：veliparib plus folfiri±bevacizumab的2阶段随机研究与转移结直肠癌中的安慰剂plus folfiri±bevacizumab

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Vera Gorbunova; J. Thaddeus Beck; Ralf-Dieter Hofheinz; Pilar Garcia-Alfonso; Marina Nechaeva; Antonio Cubillo Gracian; Laszlo Mangel; Elena Elez Fernandez; Dustin A. Deming; Ramesh K. Ramanathan; Alison H. Torres; Danielle Sullivan; Yan Luo; Jordan D. Berlin;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer [J] . Vera Gorbunova, J. Thaddeus Beck, Ralf-Dieter Hofheinz, British Journal of Cancer . 2019,第2期

机译：韦利帕利布联合FOLFIRI±贝伐单抗与安慰剂联合FOLFIRI±贝伐单抗在转移性大肠癌中的2期随机研究
2. Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer [J] . Vera Gorbunova, J. Thaddeus Beck, Ralf-Dieter Hofheinz, British Journal of Cancer . 2019,第5期

机译：更正：韦利帕利布联合FOLFIRI±贝伐单抗与安慰剂联合FOLFIRI±贝伐单抗在转移性大肠癌中的2期随机研究
3. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial [J] . The lancet oncology . 2020,第4期

机译：Upfront folfoxiri加贝伐单抗和进展后的重新引入与mfolfox6加上贝伐单抗，其次是Folfiri加贝伐单抗在治疗转移性结肠直肠癌（TRIBE2）：多期，开放标签，第3阶段，随机，受控试验
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer [O] . Vera Gorbunova, J. Thaddeus Beck, Ralf-Dieter Hofheinz, 2019

机译：韦利帕利布联合FOLFIRI±贝伐单抗与安慰剂联合FOLFIRI±贝伐单抗在转移性大肠癌中的2期随机研究
7. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial [O] . Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini, 2020

机译：Upfront folfoxiri加贝伐单抗和次曲后的重新引入与mfolfox6 plus bevacizumab，然后是Folfiri加Bevacizumab治疗转移性结肠直肠癌（Tribe2）：多期，开放标签，第3阶段，随机，受控试验

A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer

著录项

引文网络

相似文献

相关主题

期刊订阅